Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Alirocumab (Praluent®) - SMC 1147/16Formulary Group advice will be published by 31st August 2016. (Indication: for specialist use only in adults with primary hypercholesterolaemia who are at high cardiovascular risk).

Bevacizumab (Avastin®) - SMC 1135/16 - in progress. (Indication: for use in combination with paclitaxel and cisplatin in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix).

Bortezomib (Velcade®) - SMC 1075/15 - in progress (Indication: for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation).

Brivaracetam (Briviact®) - SMC 1160/16 - in progress (Indication: for adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with refractory epilepsy).

Co-careldopa (Duodopa®) - SMC 316/06 - Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results and patients are not eligible for deep brain stimulation).

Diamorphine hydrochloride (Ayendi®) - SMC 1172/16Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring).

Emtricitabine/tenofovir alafenamide (Descovy®) - SMC 1169/16Formulary Group advice will be published by 31st August 2016. (Indication: in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1).

Ibrutinib (Imbruvica®) - SMC 1150/16Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)).

Ibrutinib (Imbruvica®) - SMC 1151/16Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy).

Insulin degludec (Tresiba®) - SMC 856/13Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of diabetes mellitus in adults).

Levofloxacin (Quinsair®) - SMC 1162/16 -  Formulary Group advice will be published by 31st August 2016. (Indication: for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis as a third line treatment option after colistimethate sodium (first line) and tobramycin (second line)).

Medroxyprogesterone acetate (Sayana® Press) - SMC 896/13 - Formulary Group advice will be published by 31st August 2016. (Indication: for long-term female contraception).

Mepolizumab (Nucala®) - SMC 1149/16 - In progress. (Indication: as an add-on treatment for severe refractory eosinophilic asthma in adult patients).

Nivolumab (Opdivo®) - SMC 1120/16 - Formulary Group advice will be published by 31st August 2016. (Indication: as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab).

Nivolumab (Opdivo®) - SMC 1144/16 - In progress (Indication: for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults).

Ofatumumab (Arzerra®) - SMC 1037/15 -  In progress. (Indication: in combination with chlorambucil for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy).

Panobinostat (Farydak®) - SMC 1122/16 - Formulary Group advice will be published by 31st August 2016. (Indication: in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent).

Regorafenib (Stivarga®) - SMC 1031/15 - Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib).

Rilpivirine (Edurant®) - SMC 1168/16Formulary Group advice will be published by 31st August 2016. (Indication: in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL).

Secukinumab (Cosentyx®) - SMC 1159/16 - Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy).

Secukinumab (Cosentyx®) - SMC 1167/16Formulary Group advice will be published by 31st August 2016. (Indication: alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients whose disease has not responded to adequate trials of at least two standard DMARDs either individually or in combination).

Sorafenib (Nexavar®) - SMC 482/08Formulary Group advice will be published by 31st August 2016. (Indication: for the treatment of patients with advanced hepatocellular carcinoma who have failed or are unsuitable for surgical or loco-regional therapies).

Trastuzumab (Herceptin®) - SMC 623/10 - Formulary Group advice will be published by 31st August 2016. (Indication: in combination with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.  It is indicated for use only in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by  IHC 3+ ("HER2 high expresser"), as determined by an accurate and validated assay).

Publication schedule

This web page is updated monthly, within 7 working days of publication of Scottish Medicines Consortium advice.

END